New COVID-19 drug used to treat patients suffering from respiratory failure is in trials
Fox Business Apr. 07, 2021 – 5:06 – NeuroRX CEO Dr. Jonathan Javitt discusses the new COVID-19 drug for respiratory distress and vaccine boosters.
FDA Investigating Quality Issues That Led To Millions Of J&J Vaccines To Be Thrown Out
Cheddar News – Apr 2, 2021 02:23 pm
New COVID 19 Drug can Effectively Treat Patients – Discussion with Dr. Javitt, CEO NeuroRx
Interview with Dr. Yo – Streamed live on Feb 11, 2021
Prof Jonathan Javitt joins i24NEWS – FDA Grants Continuation of COVID-19 Trial
https://www.youtube.com/watch?v=ogvdYGj5hQQ&feature=share&fbclid=IwAR33RM6pud-jcg0K5WGpDzFq27PdTcu8rYKZ_VDQagylTubUFm7aIo1UWm4
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.
Is There Another Coronavirus Treatment? What To Know About The Fast-Tracked Drug Aviptadil
A drug that mimics a peptide produced by the bowel has been fast-tracked by the Food and Drug Administration to treat COVID-19 lung inflammation, NeuroRx Inc. announced Wednesday. The drug protects cells believed to act as a gateway for the coronavirus to attack the lungs.
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
Focusing on You: UM Tests Drug to Lessen Severity of COVID-19
University of Miami Health System
Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.
Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19.